Free Trial

Korro Bio (KRRO) Stock Price, News & Analysis

Korro Bio logo
$11.20 -0.54 (-4.56%)
As of 10:02 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Korro Bio Stock (NASDAQ:KRRO)

Key Stats

Today's Range
$11.28
$11.95
50-Day Range
$11.73
$20.93
52-Week Range
$11.13
$98.00
Volume
4,571 shs
Average Volume
99,938 shs
Market Capitalization
$105.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$102.43
Consensus Rating
Buy

Company Overview

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Korro Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

KRRO MarketRank™: 

Korro Bio scored higher than 48% of companies evaluated by MarketBeat, and ranked 676th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Korro Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Korro Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Korro Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Korro Bio is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Korro Bio is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Korro Bio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Korro Bio's valuation and earnings.
  • Percentage of Shares Shorted

    19.49% of the float of Korro Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Korro Bio has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Korro Bio has recently increased by 0.94%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Korro Bio does not currently pay a dividend.

  • Dividend Growth

    Korro Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.49% of the float of Korro Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Korro Bio has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Korro Bio has recently increased by 0.94%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Korro Bio has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Korro Bio this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Korro Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Korro Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Korro Bio is held by insiders.

  • Percentage Held by Institutions

    Only 13.18% of the stock of Korro Bio is held by institutions.

  • Read more about Korro Bio's insider trading history.
Receive KRRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter.

KRRO Stock News Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Korro Bio to Cut 20% of Workforce
Korro Bio to Cut 20% of Workforce
Chardan Capital Initiates a Buy Rating on Korro Bio (KRRO)
See More Headlines

KRRO Stock Analysis - Frequently Asked Questions

Korro Bio's stock was trading at $38.07 at the beginning of the year. Since then, KRRO shares have decreased by 69.2% and is now trading at $11.73.
View the best growth stocks for 2025 here
.

Korro Bio, Inc. (NASDAQ:KRRO) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($2.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.60) by $0.11. The business had revenue of $2.55 million for the quarter, compared to the consensus estimate of $0.13 million.

Korro Bio's top institutional shareholders include Driehaus Capital Management LLC (6.20%), Cormorant Asset Management LP (4.05%), Tri Locum Partners LP (1.37%) and Aberdeen Group plc (0.90%). Insiders that own company stock include Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal.
View institutional ownership trends
.

Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
5/07/2025
Today
5/29/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KRRO
Previous Symbol
NASDAQ:KRRO
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$102.43
High Stock Price Target
$180.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+773.2%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$81.17 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.82 million
Price / Cash Flow
N/A
Book Value
$21.19 per share
Price / Book
0.55

Miscellaneous

Free Float
8,862,000
Market Cap
$110.16 million
Optionable
No Data
Beta
2.66
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:KRRO) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners